Alpha 2.0
Login Register
» Authors » H Cody Meissner

H Cody Meissner

Explore the profile of H Cody Meissner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2054
Followers 0
Related Specialties
Pediatrics
General Medicine
Infectious Diseases
Top 10 Co-Authors
John A Branda
Elizaveta E Vaysbrot
Sunil K Sood
Raveendhara R Bannuru
Valery Lavergne
Peter J Krause
Larry K Pickering
Paul M Lantos
Yngve T Falck-Ytter
Gary P Wormser
Published In
Pediatrics
Clin Infect Dis
N Engl J Med
JAMA
Pediatr Infect Dis J
Affiliations
Soon will be listed here.
Recent Articles
1.
Anticipating the Next Pandemic
Meissner H, Kapogiannis B, Wolfe D
N Engl J Med . 2024 Jul; 391(3):196-199. PMID: 39007537
No abstract available.
2.
Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA-)-Supported Phase 2b Study Designs
Wolfe D, Arangies E, David G, Armstrong B, Scocca T, Fedler J, et al.
Clin Infect Dis . 2024 May; 79(4):928-935. PMID: 38804702
In response to the coronavirus disease 2019 (COVID-19) pandemic, vaccines were quickly and successfully developed and deployed, saving millions of lives globally. While first-generation vaccines are safe and effective in...
3.
The Beginning of a New Era in RSV Control
Meissner H
Pediatrics . 2023 Sep; 152(5). PMID: 37682622
No abstract available.
4.
Understanding Vaccine Safety and the Roles of the FDA and the CDC
Meissner H
N Engl J Med . 2022 Apr; 386(17):1638-1645. PMID: 35476652
No abstract available.
5.
Management of Pediatric Lyme Disease: Updates From 2020 Lyme Guidelines
Meissner H, Steere A
Pediatrics . 2022 Mar; 149(3). PMID: 35229121
No abstract available.
6.
Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines
Choi Y, Meissner H, Hampp C, Park H, Winterstein A
Eur J Pediatr . 2021 Aug; 181(2):841-845. PMID: 34365543
Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with CLD in their second year of life if they continue to need treatment within 6 months before...
7.
Ten Years of Newborn Screening for Severe Combined Immunodeficiency (SCID) in Massachusetts
Hale J, Platt C, Bonilla F, Hay B, Sullivan J, Johnston A, et al.
J Allergy Clin Immunol Pract . 2021 Feb; 9(5):2060-2067.e2. PMID: 33607339
Background: Massachusetts began newborn screening (NBS) for severe combined immunodeficiency (SCID) using measurement of T-cell receptor excision circles (TRECs) from dried blood spots. Objective: We describe developments and outcomes from...
8.
A Viral Pandemic, Vaccine Safety, and Compensation for Adverse Events
Meissner H
JAMA . 2021 Feb; 325(8):721-722. PMID: 33544127
No abstract available.
9.
The Facts About Vaccine Safety
Meissner H, Plotkin S
Clin Infect Dis . 2021 Jan; 72(2):309-310. PMID: 33501966
The Vaccine Compensation System evaluates true and false associations between vaccination and adverse events. The data from the system enable the calculation of the risk of serious adverse events per...
10.
Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
Krause P, Auwaerter P, Bannuru R, Branda J, Falck-Ytter Y, Lantos P, et al.
Clin Infect Dis . 2021 Jan; 72(2):185-189. PMID: 33501959
The purpose of this guideline is to provide evidence-based guidance for the most effective strategies for the diagnosis and management of babesiosis. The diagnosis and treatment of co-infection with babesiosis...